Lamotrigine (Lamictal) Dosing
Lamotrigine dosing is critically dependent on concomitant medications, with valproate requiring half the standard dose and enzyme-inducing drugs requiring double the dose due to significant drug interactions affecting glucuronidation. 1
Adult Dosing for Epilepsy
Adjunctive Therapy Dosing (Ages 13+ and Adults)
The titration schedule varies dramatically based on concomitant medications:
With Valproate (inhibits lamotrigine metabolism):
- Weeks 1-2: 25 mg every other day
- Weeks 3-4: 25 mg daily
- Week 5: 50 mg daily
- Week 6: 100 mg daily
- Week 7: 150 mg daily
- Maintenance: 200-250 mg daily 1
Without enzyme inducers or valproate:
- Weeks 1-2: 25 mg daily
- Weeks 3-4: 50 mg daily
- Week 5: 100 mg daily
- Week 6: 150 mg daily
- Week 7: 200 mg daily
- Maintenance: 300-400 mg daily 1
With enzyme-inducing AEDs (carbamazepine, phenytoin, phenobarbital, primidone):
- Weeks 1-2: 50 mg daily
- Weeks 3-4: 100 mg daily
- Week 5: 200 mg daily
- Week 6: 300 mg daily
- Week 7: 400 mg daily
- Maintenance: 400-600 mg daily 1
Monotherapy Conversion
Target monotherapy dose: 250-300 mg daily 1
When converting from enzyme-inducing AEDs, first escalate to 500 mg/day, then withdraw the inducing AED by 20% weekly over 4 weeks. Two weeks after complete withdrawal, decrease lamotrigine by no more than 100 mg/week to reach 250-300 mg/day 1.
Bipolar Disorder Dosing
Lamotrigine is FDA-approved for maintenance therapy in adult bipolar disorder, not acute mania. 2 The drug shows particular efficacy in preventing depressive episodes 3. Standard maintenance dosing is 200 mg/day after the same slow titration schedule used in epilepsy, adjusted for concomitant medications 1.
Pediatric Considerations
For children with refractory epilepsy, lamotrigine has demonstrated efficacy as adjunctive therapy at doses up to 15 mg/kg/day (maximum 400 mg/day), with approximately 40% achieving ≥50% seizure reduction 4. Generalized seizures, including absence seizures and Lennox-Gastaut syndrome, respond better than partial seizures 5, 4. The same drug interaction principles apply, requiring dose adjustments based on concomitant medications 1.
Renal Impairment Adjustments
In severe renal impairment (creatinine clearance <10 mL/min), reduce dosing to 100 mg every two days. 6 The elimination half-life doubles from approximately 25 hours to 50 hours in uremic patients. Hemodialysis significantly removes lamotrigine (17% of dose extracted), shortening half-life from 59.6 hours to 12.2 hours during dialysis 6. Consider supplemental dosing post-dialysis.
Critical Drug Interactions
Valproate increases lamotrigine levels approximately 2-fold by inhibiting glucuronidation 1, 7. Plasma levels in patients on valproate average 8.7 mg/L compared to 4.8 mg/L with enzyme inducers 7.
Estrogen-containing oral contraceptives increase lamotrigine clearance by approximately 2-fold, decreasing AUC by 52% and Cmax by 39% 1. Trough levels double during the inactive hormone week. Rifampin and protease inhibitors (lopinavir/ritonavir, atazanavir/ritonavir) similarly induce glucuronidation and require dose increases 1.
Safety Considerations
The most critical risk is serious rash, occurring in approximately 10% of patients, minimized by strict adherence to slow titration schedules 4. The incidence of serious rash requiring hospitalization in bipolar disorder studies was 0.1%, including one case of mild Stevens-Johnson syndrome 3. Never exceed recommended initial doses or escalation rates 1.
Common adverse effects include dizziness, headache, nausea, and insomnia 3. Unlike lithium, lamotrigine does not cause weight gain and generally does not require serum level monitoring 3.
Monitor patients closely when converting from immediate-release to extended-release formulations, particularly those on enzyme-inducing agents, as plasma levels may decrease 1.